	US 12,109,254 B2
	Vitamins and alpha keto acid compositions for use in a treatment program for chronic kidney disease patients
Edgar Lee Hull, Jr., Verona, WI (US); Narashima Murthy, Bangalore (IN); and Sridhara Am, Bangalore (IN)
Assigned to Edgar Hull, Verona, WI (US)
Filed by Edgar Lee Hull, Jr., Middletown, WI (US)
Filed on Sep. 14, 2022, as Appl. No. 17/945,043.
Application 17/945,043 is a division of application No. 17/061,952, filed on Oct. 2, 2020, granted, now 11,484,579.
Application 17/061,952 is a continuation in part of application No. 16/768,230, granted, now 11,253,496, issued on Feb. 22, 2022, previously published as PCT/US2018/063086, filed on Nov. 29, 2018.
Claims priority of provisional application 62/772,590, filed on Nov. 28, 2018.
Claims priority of provisional application 62/592,380, filed on Nov. 29, 2017.
Prior Publication US 2023/0023185 A1, Jan. 26, 2023
Int. Cl. A61K 38/44 (2006.01); A61K 31/122 (2006.01); A61K 31/197 (2006.01); A61K 31/198 (2006.01); A61K 31/355 (2006.01); A61K 31/405 (2006.01); A61K 31/4172 (2006.01); A61K 31/4415 (2006.01); A61K 31/455 (2006.01); A61K 31/51 (2006.01); A61K 31/519 (2006.01); A61K 31/525 (2006.01); A61K 31/714 (2006.01); A61K 33/00 (2006.01); A61K 33/04 (2006.01); A61K 33/30 (2006.01)

CPC A61K 38/443 (2013.01) [A61K 31/122 (2013.01); A61K 31/197 (2013.01); A61K 31/198 (2013.01); A61K 31/355 (2013.01); A61K 31/405 (2013.01); A61K 31/4172 (2013.01); A61K 31/4415 (2013.01); A61K 31/455 (2013.01); A61K 31/51 (2013.01); A61K 31/519 (2013.01); A61K 31/525 (2013.01); A61K 31/714 (2013.01); A61K 33/00 (2013.01); A61K 33/04 (2013.01); A61K 33/30 (2013.01); A61K 38/446 (2013.01)]

9 Claims

1. A low nitrogen protein food composition for a patient in need thereof comprising as active ingredients at least five alpha keto analogues of amino acids: a) wherein the alpha keto analogues are five magnesium salts comprising:

isoleucine is about 15.0% wt./wt.;

leucine is about 29.0% wt./wt.;

methionine is about 8.33% wt./wt.;

phenylalanine is about 1.31% wt/wt;

valine is about 16.10% wt./wt.; and

b) wherein the low nitrogen protein food composition comprises up to 500 mg daily of nitrogen

c) wherein the patient has Stage 3 kidney disease, is not on dialysis, and experiences a slowdown in the progression of said Stage 3 kidney disease;

d) wherein the patient experiences on average: a 42% reduction in blood urea nitrogen; a 23% reduction in creatinine; a 28% increase in glomerular filtration rate (GFR); and a lower tacrolimus dose for transplant patients.